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Background. In Gabon, several Ebolavirus outbreaks have occurred exclusively in the northeastern region. We
conducted a large serosurvey to identify areas and populations at risk and potential demographic, clinical, and
behavioral risk factors.
Methods. Blood samples and clinical and sociodemographic data were collected from 4349 adults and 362
children in a random sample of 220 villages in the 9 provinces of Gabon. An enzyme-linked immunosorbent assay
was used to detect Zaire ebolavirus (ZEBOV)–specific IgG, and thin blood smears were used to detect parasites.
Logistic regression was implemented using Stata software (Stata), and a probability level of ,.05 was considered to
be statistically significant.
Results. The prevalence of ZEBOV-specific IgG was 15.3% overall, increasing to 32.4% (P, .001) in forest
areas. No sociodemographic risk factors were found, but the antibody prevalence increased linearly up to 20 years of
age. Chronic arthralgia and amicrofilaremia were the only factors associated with ZEBOV seropositivity.
Conclusions. These findings confirm the endemicity of ZEBOV in Gabon and its link to the ecosystem. Human
antibody positivity would appear to be to the result of exposure to contaminated fruits.
Ebolavirus (EBOV) and Marburgvirus (MARV) are
among the most virulent pathogens for humans and
nonhuman primates, causing outbreaks of fulminant
hemorrhagic fever (HF). The EBOV genome consists of
a single negative strand of RNA that encodes 7 linearly
arranged gene products. There is only 1 known species of
MARV (Lake Victoria marburgvirus), whereas EBOV is
subdivided into 5 species: Zaire ebolavirus (ZEBOV),
Coˆte d’Ivoire ebolavirus (CIEBOV), Sudan ebolavirus
(SEBOV), Reston ebolavirus (REBOV) [1], and Bundi-
bugyo ebolavirus (BEBOV), recently discovered in
Uganda [2]. EBOV pathogenicity depends on the spe-
cies. The case-fatality rate can reach 90% with ZEBOV
infection, 50%–55% with SEBOV infection, and 26%
with BEBOV infection. CIEBOV has caused a single re-
corded human case of nonfatal HF, and REBOV does
not seem to be pathogenic for humans. After an in-
cubation period of 4–6 days, clinical manifestations
occur in 3 successive phases, which often overlap. Dis-
ease onset is characterized by general symptoms, such as
pyrexia, headache, arthralgias, and myalgias. The second
phase begins 2–4 days later, with gastrointestinal symp-
toms and a morbilliform rash. In general, the third,
terminal phase begins 5–7 days after onset, with hem-
orrhagic manifestations usually leading to death within
3–5 days [3, 4]. After lengthy and laborious convales-
cence, survivors developed a variety of sequelae,
including persistent arthralgias [5].
To date, 16 outbreaks of EBOV infection and 9 out-
breaks of MARV infection have been reported [6].
Since the discovery of EBOV in 1976 in Nzara (Sudan)
and Yambuku (Democratic Republic of Congo
[DRC]) [7, 8], epidemics have been reported in other
central African countries. ZEBOV infection epidemics
have only been recorded in Gabon, RC, and DRC,
whereas SEBOV infection epidemics have occurred in
Sudan and Uganda, and a BEBOV infection epidemic
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was recorded in Uganda. During 1994–2005, northeastern
Gabon and northwestern RC experienced a total of 7 outbreaks.
Four outbreaks occurred in Gabon during 1994–2002,
affecting .20 villages and towns, with 208 cases and 151 deaths
(overall case-fatality rate, 72.6%) [9–13]. During 2001–2002,
outbreaks consisted of multiple independent introductions of
the virus into human populations [14].
Since the first epidemic in 1976, many serosurveys have been
conducted to understand EBOV circulation and to identify factors
associated with human outbreaks. The results vary according to
the type of test used. Immunofluorescent antibody test (IFAT)-
based surveys showed higher prevalence rates (up to 33%) than
did enzyme-linked immunosorbent assay (ELISA)–based studies
[15–21], but ELISA is more specific and sensitive than are
IFAT tests [22]. For instance, in Gabon, of 253 and 213 human
serum samples collected in 1980 in Ambinda and in 1985 in
Franceville, both situated in a nonepidemic area (Haut Ogooue
Province, southeastern Gabon) 6.3% and 10.3% of samples,
respectively, were IFAT positive for anti-EBOV IgG [19–23].
Another IFAT-based survey showed an antibody prevalence of up
to 21% [16]. In contrast, ELISA-based serosurveys of epidemic
areas have given seroprevalence rates of 1.2%–16.6% [11, 24–26].
Similarly, in an IFAT-based survey conducted during 1985–1987
in 6 central African countries, high prevalence rates were found in
nonepidemic localities: 32.7% of 327 serum samples in Bangui,
Central African Republic (CAR) [16] and 21.3% of 4295 serum
samples collected in CAR [20]. The seroprevalence was highest in
forest areas, especially among hunters, identifying this ecosystem
as at risk and the main source of contamination in humans
[18, 27]. Pygmy populations (mainly hunter-gatherers) living
in the rainforest had a higher seroprevalence than did farmers
[17, 18, 21]. The 2001–2002 epidemics first affected hunters who
handled infected animal carcasses [14, 28].
Recently, with a specific ELISA method, we showed that
ZEBOV IgG positivity in rural human populations of Gabon is
associated with cellular and humoral immune responses. We
suspected that this seropositivity could be attributable to
asymptomatic infection, mild disease, or simple exposure to viral
particles [29]. In our study, we attempted to identify potential
geographic, demographic, behavioral, and clinical risk factors for
ZEBOV seropositivity.
MATERIALS AND METHODS
Area of Study
The survey covered rural Gabonese populations and included all
ecosystems. Gabon is located in central Africa, is crossed by the
equator, is limited to the west by an 800-km Atlantic coast, and
has a surface area of 267 667 km2, nearly 80% of which is covered
by rainforest [30]. Gabon is divided into 9 provinces, 47 de-
partments, 50 municipalities, and 2048 villages. The population
is 1.5 million inhabitants, 73% of whom live in urban areas.
Rural populations, located along roads and rivers, belong to 10
ethnic groups with different customs, faiths, and languages.
Subsistence farming, hunting, gathering, and fishing are the
main activities. Geographically, the country is divided into
3 ecosystems: forest, savannah, and lakeland. The forest extends
from west to east and is divided into grassland and deep
forest. Grassland lies at low elevations, forming a coastal strip
20–300 km wide, juxtaposing the deep forest, which is composed
of mountains and plateaus, extending to the Congo border. The
mountains form a band 60–100 km wide, parallel to the coast.
The plateaus are divided into interior and northeastern forests.
The deep forest is characterized by the presence of okoume´ trees,
except in the northeast. The south and southeast contain scat-
tered areas of savannah and steppe. Lakeland, a coastal and
continental marine ecosystem, is located in Estuaire, Ogooue´
Maritime, and Moyen Ogooue´ Provinces, around the mouth of
the Ogooue´ River (Figure 1).
Ethical Considerations
The study protocol was approved by the Gabonese Ministry
of Health (research authorization 00093/MSP/SG/SGAQM)
(Supplementary Figure 1). The health director of each province
and the chiefs of each village received written information. In each
village, the inhabitants received information on the study, and
individual written consent was required for obtainment of blood
samples (parental consent for children) (Supplementary Figure 2).
Study Population
The survey was conducted by a multidisciplinary team, in-
cluding a doctor from the Gabonese Ministry of Health, a nurse,
an epidemiologist, a veterinarian, and laboratory technicians,
during nine 1-month field missions (from June 2005 through
September 2008). Stratified random sampling was used. The
stratification was based on the 9 provinces, and the sample size
was calculated as n5 e 2 [p (1-p)]/e 2; with e5 1.96 (a risk, 5%),
e (precision) 5 2%, and p (expected prevalence) of 2%–10%.
Then, in each province, 10–40 villages were randomly selected.
All healthy volunteers aged .16 years who had been residing in
the village for .1 year and who accepted obtainment of blood
samples were included in the study. Another specific field mis-
sion was performed to enroll children who were randomly se-
lected from 6 villages of Ogooue´ Ivindo Province. In addition to
a free medical examination, blood smears for malaria diagnosis
and field blood typing were proposed, and basic medicines were
provided to all participants. All the villages were geolocated.
Epidemiological Records
Questionnaire. Adult participants were asked to complete
an administered 2-page questionnaire, generally in French or in
the local language, with the help of a local health care worker
(Supplementary Figure 3). The following information was col-
lected: demographic data (age, sex, marital status, and level of
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education), geographic location (name of the village, length of
residence, and province), tattooing and scarification, and con-
tact with wild animals (monkeys, duikers, and bats) through
hunting, eating, cooking, butchering, or pet-keeping. Only age
and sex data were collected for children.
Medical Data. All the participants were interviewed to re-
cord medical history (hemorrhagic fever, prolonged fever,
chronic arthralgias, skin diseases, reasons for hospitalization if
any, adult Loa loa worm crossing the subconjunctiva, and
swellings). The participants were also briefly examined for
anemia, lymphadenopathies, cutaneous and neurological
disorders, and swelling of joints or abdominal organs.
Laboratory Analyses
Blood Sample Collection. The team resided in the main
town of each administrative region, and laboratory facilities
were established inside the general hospital. Blood samples were
collected, usually at the village health care center, in two 7-mL
EDTA Vacutainer tubes (VWR International). The tubes were
stored in the dark at 4C until arrival at the laboratory. Plasma
was obtained by centrifugation (10 minutes, 2000 g) each
evening and stored in aliquots at 220C. At the end of the
field mission, the aliquots were transferred to the Centre
International de Recherches Me´dicales de Franceville, Gabon, on
dry ice, and were stored at 280C until analysis.
ZEBOV-Specific IgG Detection and Cutoff Calculation.
An IgG ELISA method was used, as described elsewhere [22],
with antigens kindly provided by the Special Pathogens Branch,
Centers for Disease Control and Prevention. In brief, Maxisorp
plates (Nunc) were coated with ZEBOV antigens diluted 1:1000
in phosphate-buffered saline (PBS) overnight at 4C. Control
plates were coated with uninfected Vero cell culture antigens in
the same conditions. Serum samples were diluted 1:1600 in 5%
nonfat milk in PBS-Tween 20 (0.1%) and were incubated in
the wells overnight at 4C. Binding was visualized by using
a peroxidase-labeled antibody to human IgG (Sigma) and the
TMB detector system (Dynex Technologies). Optical density
(OD) was measured at 450 nm with an ELISA plate reader. For
each sample, we calculated the corrected OD as the OD of the
antigen-coated well minus the OD of the corresponding con-
trol well. A panel of 104 serum samples from inhabitants of
Marseille, France, who had never visited Africa, were used as
negative controls for cutoff calculation (all tested negative), with
Western blot confirmation, as described elsewhere [29].
Parasitological Analyses. L. loa microfilaremia was de-
tected by direct reading of 10 lL of fresh uncoagulated blood
Figure 1. Map of Gabon with limits of administrative regions and location of villages surveyed (red circles), strictly georeferencied and generated by
MAPINFO. All ecosystems are represented in thorough colour. Villages where children under 16 years were included are indicated by yellow circles.
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between a microscope slide and coverslip, using an optical mi-
croscope with a x100 objective. When microfilaria were found,
their total number on the slide was multiplied by 100 to express
parasitemia as mf/mL of blood. When no microfilaria were
found, Knott’s concentration technique was used: 1 mL blood
was diluted with 9 mL of PBS in a conical tube, and 200 lL of
saponin (2%) was added to induce hemolysis. The tube was then
centrifuged (10 minutes, 500 g), and the supernatant was dis-
carded. The entire pellet was scanned for microfilaria under
a microscope with a x100 objective. Filarial speciation was based
on size and movement.
To detect Plasmodium falciparum, thick and thin blood films
were stained with Giemsa and examined at x1000 magnification.
A sample was considered to be negative if no parasites were
detected after examining 1000 erythrocytes.
Statistical Analysis
To take into account the linear association between ZEBOV
seroprevalence and the age group, we used a trend test across
ordered groups. All variables were screened to describe our
population, and the v2 test (Fisher’s exact test when appropri-
ate) was used to identify statistical associations with ZEBOV
seroprevalence. Overall and subgroup-specific ZEBOV sero-
prevalence rates were estimated. Potential differences between
risk factors and seroprevalence by ecosystem were found. Mul-
tivariate logistic regression models stratified by ecosystem were
constructed from risk factors with a significance of #0.10 in
univariate analysis, using a backwards stepwise elimination
procedure. Odds ratios (ORs) and exact 95% confidence inter-
vals (CIs) were used to assess the association between potential
risk factors and ZEBOV seroprevalence. P, .05 was considered
to be statistically significant. Stata software, version 10 (Stata)
was used for all analyses.
RESULTS
Characteristics of the Study Population
Ten field missions lasting a total of 38 weeks were performed
from June 2005 through September 2008. The survey covered
220 villages, representing 10.7% of all villages in Gabon. We
enrolled a total of 4349 adults and 362 children, representing
1.2% of the 387 670 rural inhabitants in Gabon. From 0.6%
through 1.9% of inhabitants in each province were enrolled
(Table 1). A total of 3458 individuals (79.5%) were enrolled in
the forest ecosystem, 448 (10.3%) in savannah, and 443 (10.2%)
in lakeland. Fourteen outbreak villages, with a total of 265 in-
habitants, were also selected. The male-to-female sex ratio of the
adult population was 0.89, and their mean age (6standard de-
viation [SD]) was 46 6 14 years (range,15–90 years). They in-
cluded 1273 hunters (29.3%), and 2874 participants (69%) had
resided in their village for .10 years (Table 2). Among the 362
children enrolled, 56.2% were male (sex ratio, 1.3), 51 (12.9%)
were aged 1–5 years, 156 (39.5%) were aged 6–10 years, 168
(42.5%) were aged 11–15 years, and 20 (5.1%) were aged 16–20
years.
Geographic Distribution of ZEBOV Seroprevalence
The overall prevalence of ZEBOV-specific IgG in the study
population was 15.3%.
The highest prevalence (21.5%) was found in Ngounie´, and
the lowest (1.5%) was in Ogooue´ Maritime. The prevalence was
20.1% in the epidemic Ogooue´ Ivindo Province and 18.9% and
19.2% in the nearby Woleu Ntem and Ogooue´ Lolo Provinces,
respectively (Table 3).
The seroprevalence was significantly higher (P, .0001) in the
forest region (17.6%) than in savannah (10.5%) and lakeland
(2.7%). The seroprevalence was significantly lower (P , .0001)
in lakeland than in savannah. In the forest ecosystem, the
Table 1. Regional Distribution of the Study Population
Provinces
Villages Population
Total Surveyed % Total Tested %
Estuaire 100 30 30 53 459 314 0.6
Haut Ogooue´ 171 18 10.5 50 196 364 0.7
Moyen Ogooue´ 226 31 13.7 31 089 618 1.9
Ngounie´ 233 22 9.4 52 115 455 0.8
Nyanga 113 16 14 20 544 403 1.9
Ogooue´ Ivindo 197 41 20.8 34 540 618 1.8
Ogooue´ Lolo 190 18 9.5 36 877 421 1.1
Ogooue´ Maritime 188 10 5.3 12 940 205 1.6
Woleu Ntem 630 34 5.4 95 910 951 0.9
TOTAL 2048 220 10.7 387 670 4349 1.02
Table 2. Sociodemographic Characteristics of the Study Pop-
ulation (n 5 4349) and Distribution According to the Ecosystem
Characteristics Number %
Sex Male 2049 47.1
Female 2300 52.9
Age ,15 362
15–30 746 17.1
31–45 1159 26.7
46–60 1695 39
.60 749 17.2
Occupational activity Nonhunters 3076 70.7
Hunters 1273 29.3
Length of residence ,10 years 1281 31
$10 years 2874 69
Geographic location Lakeland 443 10.2
Savannah 448 10.3
Forest 3458 79.5
Grassland 918 21.1
Deep forest 2540 58.4
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seroprevalence was significantly lower (P , .0001) in grassland
than in mountains and interior and northeastern forest zones
but higher (P, .0001) than in lakeland (Table 4). There was no
difference between grassland and savannah (P 5 .3) or between
mountains or interior and northeastern forest. No statistically
significant difference in seroprevalence was observed between
epidemic (20%) and nonepidemic (19.6%) villages of the
northeastern forest in Ogooue´ Ivindo Province (P 5 .9) or be-
tween villages of the 1996–1997 outbreaks (18%) and villages of
the 2001–2002 outbreaks (20.1%; P 5 .6).
Sociodemographic Characteristics
Univariate analysis of the adult population showed no correla-
tion between seropositivity and sociodemographic factors in the
deep forest or savannah. In grassland, the seroprevalence was
significantly higher in male individuals (OR, 1.75; 95% CI, 1.16–
2.63; P 5 .007) and in individuals who ate bats (OR, 1.74; 95%
CI, 1.09–2.75; P 5 .02) (Supplementary Table 1). In lakeland,
individuals who butchered game had a significantly higher se-
roprevalence, compared with other participants (P 5 .02)
(Supplementary Table 2).
The overall seroprevalence in the child population was 12.9%
(95%CI, 9.8%–16.7%), with no statistically significant difference
between male (12.2%) and female individuals (13.9%). The
youngest seropositive person was 2 years of age. Increasing age
was an important risk factor, with a statistically significant dif-
ference (P5 .02) across the age groups. A linear association was
observed when we added individuals aged #20 years who lived
in the same department and were had samples obtained during
the initial field study. For persons .20 years of age, the trend
was sinusoidal, both overall and in each ecosystem (Figure 2).
Medical Data
None of the participants declared a history of Ebola-like HF or
had been in contact with a known EBOV-infected person. As-
sociations between the seroprevalence rate and the participant’s
medical history were examined separately in each ecosystem. In
the deep forest, eye worm, joint swelling, and abdominal pain
were significantly more frequent in IgG-positive persons
(P5 .03) (Supplementary Table 3), whereas eye worm was more
frequent in northeastern forest (OR, 1.42 95% CI, 1–2; P5 .05)
and joint swelling was more frequent in the mountain forest
(OR, 2.33; 95% CI, 1.07–5.08; P 5 .03). Abdominal pain
(OR, 0.42; 95% CI, .18–.99; P 5 .04) and chronic arthralgias
(OR, 2.94; 95% CI, 1.40–6.17; P5 .003) were significantly more
frequent in savannah (Supplementary Table 4). No medical
risk factors for EBOV seropositivity were noted in the other
ecosystems (interior forest, grassland, and lakeland).
Parasitological Findings
Overall, 3.8% of individuals had both specific IgG and L. loa
carriage. This association was significantly stronger in the forest
(P , .0001). Among IgG-positive individuals, 25% were L. loa
carriers, whereas 17% of L. loa carriers had specific IgG. One
percent of individuals had both specific IgG and P. falciparum
carriage. In lakeland, a positive correlation was noted between
IgG positivity and L. loa carriage (OR, 5.4; 95% CI, 1.70–17.3;
P 5 .007). Among the 700 amicrofilaremic individuals with eye
worm but L. loa negativity, 20% (n 5 141) were ZEBOV IgG
positive. In the deep forest ecosystem, the risk of being ZEBOV
IgG positive was 1.25-fold higher among amicrofilaremic
individuals than among microfilaremic individuals (95% CI,
0.99–1.56-fold; P 5 .054) (Supplementary Table 5).
Logistic Regression Analysis
Multivariate analyses were performed separately for each eco-
system when possible. The only variables that remained signif-
icantly associated with ZEBOV IgG positivity after adjustment
for other risk factors were amicrofilaremia in deep forest
Table 3. Prevalence of ZEBOV-Specific IgG in Gabon According
to the Administrative Region
Provinces 1/Total Prevalence (%) 95% CI Extreme limits
Estuaire 48/314 15.3 11.5–19.8 0–27.5
Haut Ogooue 46/364 12.6 9.4–16.5 0–26.9
Moyen Ogooue 36/618 5.8 4.1–8 1–13.2
Ngounie 98/455 21.5 17.8–25.6 12.1–32.4
Nyanga 51/403 12.7 9.6–16.3 0–21.2
Ogooue Ivindo 124/618 20.1 17–23.4 7.7–25.6
Ogooue Lolo 81/421 19.2 15.6–23.3 6.1–28.3
Ogooue Maritime 3/205 1.5 .3–4.2 0–6.9
Woleu Ntem 180/951 18.9 16.5–21.6 11.9–26.1
TOTAL 667/4349 15.3 14.3–16.5 0–32.4
Table 4. Prevalence of ZEBOV-Specific IgG in Gabon According to the Ecological Region
Ecosystems Villages 1/Total Prevalence (%) 95% CI Min–Max P-value
All population 220 667/4349 15.3
Lakeland 24 12/443 2.7 1.4–4.7 0–13.2 , .0001
Savannah 22 47/448 10.5 7.8–13.7 0–16.1
Forest 174 608/3458 17.6 16.3–18.9 3.8–32.4
Grassland 62 114/918 12.4 10.3–14.7 3.8–30 , .0001
Deep forest 112 494/2540 19.4 18–21.2 5–32.4
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(adjusted OR, 1.26; 95% CI, 1–1.59; P 5 .04) and chronic
arthralgias in grassland (adjusted OR, 1.88; 95% CI, 1–3.55;
P 5 .05) and savannah (adjusted OR, 3.40; 95% CI, 1.58–7.29;
P 5 .002) (Table 5).
DISCUSSION
We conducted a serosurvey of Zaire ebolavirus in 220 rural vil-
lages in Gabon, to define and characterize the geographic dis-
tribution and circulation of ZEBOV and to identify risk factors
for human exposure.
The prevalence of ZEBOV-specific IgG was surprisingly
high, at 15.3% overall. It reached 32.4% in one village, the
highest rate ever detected with an ELISA method. Seropreva-
lence rates in previous ELISA-based studies conducted in CAR
and DRC never exceeded 20% [15, 17, 21]. In Gabon, during
the second ZEBOV outbreak, 205 samples were collected in
3 villages, and ZEBOV IgG was found with this method in
14.9%–30% of individuals [10]. In contrast, a prevalence of only
1.4% was found in 8 villages in the Gabonese outbreak area [25].
Of 1147 serum samples collected during 1981–1997 in 6 rural
communities in central, northeastern, and western Gabon,
only 14 (1.2%) contained ZEBOV-specific IgG [26]. This dis-
crepancy may be attributable to differences in the screening and
population sampling methods (random vs nonrandom). Our
survey included rural populations in all ecosystems and used the
most specific available ELISA method.
The test used here lacks cross-reactivity with other known
EBOV species and with MARV [22]. Recently, a Western blot
Figure 2. A, Prevalence of ZEBOV-specific IgG, by age, in children group. B, Overall prevalence of ZEBOV-specific IgG, by age, in adults group. C,
Prevalence of ZEBOV-specific IgG, by age in adults group and by ecosystem.
Table 5. Adjusted Seroprevalence and Odds Ratios (OR) for the
Presence of Zaire Ebolavirus Antibodies According to Potential
Risk Factors Stratified by Ecosystem, in Gabon
Ecosystem
Risk
factor
Adjusted
OR
95%
CI
P
value
Deep forest Sex Male 0.83 .68–1 .06
Female Referent
Nodes Yes 2.85 .98–8.3 .054
No Referent
Amicrofilaremia Yes 1.26 1–1.59 .04
No Referent
Grassland Sex Male 0.55 .3–1.02 .06
Female Referent
Fever Yes 0.51 .22–1.15 .1
No Referent
Arthralgias Yes 1.88 1–3.55 .05
No Referent
Savannah Abdominal pain Yes 0.51 .21–1.22 .13
No Referent
Arthralgias Yes 3.40 1.58–7.29 .002
No Referent
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study confirmed its specificity on highly diluted serum samples
(1:1600), and memory T cells responses were found in IgG-
positive individuals [29]. Furthermore, there was no difference
in the ranges of antibody titers between persons with and
without a history of HF [31].
Marked variability in seroprevalence rates was noted across
the administrative regions in this survey, suggesting that specific
surveillance programs should be focused on particular regions.
Regions with a high prevalence (Ngounie, Woleu Ntem, Ogooue
Ivindo, and Ogooue lolo) were mainly situated in the forest
ecosystem. Previous serosurveys, together with the geographic
pattern of outbreaks, have highlighted the potential role of the
ecosystem [18, 27, 32], and an increased risk among forest
populations has previously been described [15, 18]. Our study
confirms that the forest, particularly the deep forest, is the en-
vironment most at risk. This is the area harboring animals
susceptible to the virus, such as great apes and bats, the latter
representing a viral reservoir.
Previous studies have shown a higher prevalence in adults,
women, and hunter-gatherers [15, 17, 20]. In contrast, we found
no role of sex or activity. There is no individual susceptibility,
but susceptibility at the population scale.
No statistically significant difference was observed between
children and adults. Antibodies appeared early, from 2 years of
age, and their prevalence increased linearly until 20 years, then
remained stable. Children appear to be exposed as soon as they
become autonomous. The high seroprevalence among children
indicates the same source(s) of exposure as in adults, either
inside or near villages.
Both arthralgias and amicrofilaremia were associated with
EBOV seropositivity. Arthralgias were described both among
fatalities during the Kikwit (DRC) outbreak and among survi-
vors, in whom they were sometimes long-lasting [3, 5]. In our
study, arthralgias were the only clinical factor associated with
IgG seropositivity. They may be because of the long-term re-
action to the virus, as described with other viruses [33, 34],
rather than being a symptom of mild infection. Athralgias are
also encountered in many other chronic tropical infectious
diseases, such as loiasis. Alternatively, arthralgias may have been
related to loaisis, which was highly prevalent in our population.
L. loa amicrofilaremia also influenced ZEBOV seropositivity.
Amicrofilaremic status is generally associated with humoral and
cellular responsiveness [35, 36]. Immune anergy associated with
loaisis could lead to undetectable ZEBOV-specific IgG levels
and, thus, to an underestimation of the prevalence.
No difference in seroprevalence was found between epidemic
and nonepidemic areas, indicating an animal source prevalent
throughout the country and to exposure to a less lethal or
nonlethal strain [2, 37–39], although a cross-reactive antibody
response cannot be out-ruled.
Great ape infection is often lethal, and direct contact with
humans is rare. Fruits bats therefore represent the most likely
common animal source of ZEBOV exposure. These animals,
previously identified as a potential reservoir [40], are abundant
in the forest ecosystem and consume fruits on trees located in or
around villages. Infected fruits bats led to the 2007 Luebo out-
break in DRC [41] and have been implicated in many filovirus
outbreaks in Africa. Seropositive participants in our survey
could have been exposed to low viral inocula, inactivated virus,
or isolated viral antigens while gathering or consuming fruits
contaminated by bat saliva. Studies of epidemic areas are un-
derway in an attempt to isolate the virus from both humans
and bats.
In conclusion, the widespread ZEBOV seropositivity observed
in rural Gabon suggests that outbreaks may potentially occur
anywhere in the country. Clinical awareness and surveillance
programs should be implemented in all apparent areas of en-
demicity. Such programs should provide training for all health
care workers to facilitate early outbreak recognition and patient
treatment and should be adapted to the ecosystem and region.
Supplementary Data
Supplementary Data are available at The Journal of Infectious Diseases
online.
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